Aronem 500 mg IV Injection (Meropenem) – ACI Limited

1. About Aronem 500 mg (Meropenem)

Aronem 500 mg Injection contains Meropenem Trihydrate 500 mg — a carbapenem-class broad-spectrum beta-lactam antibiotic for intravenous use, manufactured by ACI Limited, Bangladesh. The 500 mg vial is used for moderate serious infections, paediatric dosing, and renal dose adjustment in adult patients with impaired kidney function where the 1 gm dose would be excessive.

As a carbapenem, meropenem 500 mg provides coverage against ESBL-producing Gram-negative organisms, Pseudomonas aeruginosa, and most clinically relevant anaerobes — making it essential for hospital-acquired infections and empirical therapy in high-risk settings. The 500 mg dose maintains full carbapenem spectrum while allowing dose titration in renal impairment or in less severe infection contexts.

2. Mechanism of Action

Meropenem inhibits bacterial cell wall peptidoglycan synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-2 and PBP-3. Its chemical structure provides stability against most beta-lactamases (ESBLs, AmpC, plasmid-mediated cephalosporinases), enabling activity against organisms resistant to third-generation cephalosporins and aztreonam. Bactericidal action with time-dependent killing — efficacy correlates with the fraction of the dosing interval in which free drug concentration exceeds the organism's MIC.

3. Dosage and Administration

Adults — standard (serious infections, eGFR >50): 500 mg IV every 8 hours (TDS) — total 1.5 gm/day. For severe infections, 1 gm TDS preferred (use Aronem 1 gm).

Renal dose adjustment (using 500 mg vials):

• eGFR 26–50 ml/min: 1 gm (2 × 500 mg vials) IV every 12 hours
• eGFR 10–25 ml/min: 500 mg IV every 12 hours
• eGFR <10 ml/min / haemodialysis: 500 mg IV every 24 hours; give supplement after HD session

Paediatrics (>3 months, <50 kg): 10–20 mg/kg IV every 8 hours (max 500 mg per dose for non-meningitis; 40 mg/kg or 2 gm for meningitis).

Reconstitution: Reconstitute 500 mg vial in 10 ml sterile water for injection; further dilute in 50–250 ml NS or D5W. Infuse over 15–30 min (standard) or 3–4 hours (extended infusion). Use reconstituted solution within 1–8 hours at room temperature or 24 hours at 2–8°C.

4. Indications

• Moderate hospital-acquired infections in patients with normal renal function requiring 500 mg TDS
• Renal dose adjustment in patients with eGFR <50 ml/min who need meropenem therapy
• Paediatric use (weight-based dosing per kg)
• Complicated UTI, intra-abdominal infections, pneumonia, skin/soft tissue infections — moderate-to-severe presentations
• Febrile neutropenia (paediatric oncology)

5. Contraindications

• Hypersensitivity to meropenem, other carbapenems, or beta-lactam antibiotics
• History of severe allergic reaction to penicillin — use with caution (cross-reactivity <1%)

6. Warnings and Precautions

Renal dosing: Dose adjustment is mandatory when eGFR <50 ml/min. The 500 mg vial facilitates precise renal dose adjustment more conveniently than splitting 1 gm vials.

Valproate interaction: Meropenem reduces valproate levels by 50–90% — contraindicated in epileptic patients on valproate. Consider switching anticonvulsant to levetiracetam during meropenem therapy.

Seizures: Higher risk in renal impairment and CNS pathology. Renal dose adjustment with 500 mg vials reduces seizure risk vs underdosed 1 gm in renal impairment.

C. difficile colitis: Broad-spectrum therapy risk. Monitor for diarrhoea.

Antibiotic stewardship: Carbapenem use should be culture-guided. Step-down to narrower agents when sensitivities available.

7. Side Effects

Common: Diarrhoea, nausea, vomiting, headache, injection site phlebitis.

Uncommon: Elevated transaminases/ALP, rash, pruritus, oral candidiasis.

Rare but serious: Seizures (especially in renal impairment if under-dose-adjusted), SJS/TEN, anaphylaxis, C. difficile colitis, blood dyscrasias.

8. Key Drug Interactions

• Valproic acid: Critical reduction in valproate levels — contraindicated in epilepsy patients on valproate
• Probenecid: Increases meropenem AUC and half-life — avoid concurrent use
• Warfarin: Monitor INR — possible INR alteration during carbapenem therapy

9. Meropenem and Antibiotic Resistance

Resistance to meropenem occurs through: (1) carbapenemase production (KPC, NDM-1, OXA-48, VIM/IMP metallobeta-lactamases), (2) loss of outer membrane porins reducing permeability, (3) efflux pump upregulation. Carbapenemase-producing organisms (CPOs) including NDM-1 (common in South Asia) are not susceptible to meropenem. Cultures and sensitivity testing are essential before initiating therapy, with carbapenem use guided by stewardship principles to preserve efficacy.

10. Storage

• Store below 30°C, protected from moisture. Do not freeze.
• Reconstituted: use within 1–8h (room temp) or 24h (2–8°C). Do not freeze reconstituted solution.

Frequently Asked Questions (FAQ)

Q1: When is Aronem 500 mg used instead of Aronem 1 gm?

Aronem 500 mg is used in three main scenarios: (1) Renal dose adjustment — patients with eGFR 10–50 ml/min require reduced meropenem doses (500 mg Q12h for eGFR 10–25, 500 mg Q24h for eGFR <10) where the 500 mg vial provides exact dosing; (2) Paediatric patients — weight-based dosing (10–20 mg/kg) in children under 50 kg often results in doses closer to 500 mg per dose; (3) Moderate (not severe) infections in adults where 500 mg TDS provides adequate therapy without the cost of three 1 gm vials.

Q2: How does meropenem 500 mg compare to imipenem/cilastatin?

Meropenem and imipenem are both carbapenems with similar spectrum, but meropenem has important advantages: superior Pseudomonas aeruginosa activity, lower seizure risk (no need for cilastatin renal protection component), approved for bacterial meningitis (imipenem is not), better Gram-negative coverage overall. Meropenem is the preferred carbapenem for CNS infections and Pseudomonas. Imipenem retains slightly better Gram-positive (including Enterococcus faecalis) activity in some studies.

Q3: Can Aronem 500 mg be given as IV bolus or only as infusion?

Meropenem can be administered as either IV bolus injection (over 3–5 minutes, reconstituted to 50 mg/ml) or IV infusion (over 15–30 minutes diluted in 50–250 ml, or extended infusion over 3–4 hours). Extended infusion (3–4 hours) is increasingly used in ICU settings for high-MIC organisms to optimise pharmacodynamic target attainment (maximise T>MIC). Standard practice in Bangladesh hospitals is 15–30 minute infusion.

Q4: What organisms does meropenem 500 mg NOT cover?

Despite its broad spectrum, meropenem does not cover: MRSA (methicillin-resistant S. aureus — requires vancomycin/teicoplanin), Enterococcus faecium (VRE), Stenotrophomonas maltophilia (intrinsically resistant), carbapenemase-producing organisms (NDM, KPC, OXA-48, VIM/IMP strains), and atypical organisms (Mycoplasma, Chlamydia, Legionella — carbapenems do not enter intracellular compartments effectively).